Pentixapharm: Q3 review; an extra dose of upside; chg. - NuWays AG Research
Bildkälla: Stockfoto

Pentixapharm: Q3 review; an extra dose of upside; chg. - NuWays AG Research

Pentixapharm's Q3 update reinforces the BUY case ahead of PANDA's start and potential partnering in 2027. Regulatory preparations have advanced, new oncology data strengthen the opportunity beyond primary aldosteronism (PA), and the convertible extension provides greater financial flexibility.

Clinical execution and partnering remain the next opportunities for a re-rating. The core PentixaFor opportunity is unchanged, with broader PA screening supporting demand for a scalable alternative to invasive subtyping. Oncology progress offers additional upside outside the existing valuation.

Reiterate BUY with an unchanged rNPV-based PT of € 7.20.
Börsvärldens nyhetsbrev